Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
CohBar, Inc is a biotechnology business based in the US. CohBar shares (CWBR) are listed on the NASDAQ and all prices are listed in US Dollars. CohBar employs 12 staff and has a market cap (total outstanding shares value) of USD$86.2 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Mobile users
Latest market close | USD$1.27 |
---|---|
52-week range | USD$0.87 - USD$4.25 |
50-day moving average | USD$1.2223 |
200-day moving average | USD$1.3492 |
Wall St. target price | USD$6.38 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-0.347 |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.27 from 2020-12-09
1 week (2021-01-09) | N/A |
---|---|
1 month (2020-12-18) | -9.93% |
3 months (2020-10-16) | 29.72% |
6 months (2020-07-17) | -25.29% |
1 year (2020-01-17) | -45.02% |
---|---|
2 years (2019-01-18) | -65.95% |
3 years (2018-01-18) | 6.05 |
5 years (2016-01-16) | N/A |
Gross profit TTM | USD$0 |
---|---|
Return on assets TTM | -38.85% |
Return on equity TTM | -101.77% |
Profit margin | 0% |
Book value | $0.328 |
Market capitalisation | USD$86.2 million |
TTM: trailing 12 months
There are currently 2.1 million CohBar shares held short by investors – that's known as CohBar's "short interest". This figure is 9.9% up from 1.9 million last month.
There are a few different ways that this level of interest in shorting CohBar shares can be evaluated.
CohBar's "short interest ratio" (SIR) is the quantity of CohBar shares currently shorted divided by the average quantity of CohBar shares traded daily (recently around 485675.17564403). CohBar's SIR currently stands at 4.27. In other words for every 100,000 CohBar shares traded daily on the market, roughly 4270 shares are currently held short.
However CohBar's short interest can also be evaluated against the total number of CohBar shares, or, against the total number of tradable CohBar shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CohBar's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 CohBar shares in existence, roughly 40 shares are currently held short) or 0.0472% of the tradable shares (for every 100,000 tradable CohBar shares, roughly 47 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against CohBar.
Find out more about how you can short CohBar stock.
We're not expecting CohBar to pay a dividend over the next 12 months.
Over the last 12 months, CohBar's shares have ranged in value from as little as $0.87 up to $4.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CohBar's is 2.6745. This would suggest that CohBar's shares are significantly more volatile than the average for this exchange and represent a higher risk.
CohBar, Inc., a clinical stage biotechnology company, engages in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial-derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases, CB5064 analogs for COVID-19 associated ARDS, MBT5 analogs for CXCR4-related cancer and orphan diseases, and MBT3 analogs for cancer immunotherapy. The company was founded in 2007 and is headquartered in Menlo Park, California.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.